Google Health and Germany's ZEISS Group jointly announced the successful development of the world's first AI-integrated pathological diagnostic microscope—AIMscope (Artificial Intelligence Microscopy Platform). Equipped with deep learning algorithms, this device can identify cancerous cells in real time during microscopic observation, achieving a diagnostic accuracy rate of 99.7%. It has received FDA approval for clinical auxiliary diagnosis.

: Built-in neural processing unit enables malignant cell detection within 0.3 seconds per cell.

: Supports simultaneous analysis of optical, fluorescence, and digital pathological images.

: Complex cases can be instantly referred to a global specialist consultation platform.

In blind tests involving 20,000 breast tissue samples:

: Can be deployed in primary hospitals to address shortages of pathologists.

: Built-in training module provides real-time annotation of pathological features.

: First batch of devices will be donated to medical centers in African countries.

Nobel Laureate in Medicine Harald zur Hausen stated, "This is a milestone in digital pathology. The integration of artificial intelligence and microscopy will redefine disease diagnosis paradigms."

Mass production is expected to begin in the second quarter of 2025, with a unit price 30% lower than traditional high-end pathological microscopes.